FDA 483 - Georgia Eye Bank, Inc. - April 30, 2026

An FDA inspection of Georgia Eye Bank, Inc. in Atlanta, GA, revealed a significant deficiency in its quality program. The firm failed to investigate deviations related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) and did not evaluate temperature alarms in its processing rooms. This indicates a lack of adherence to current good tissue practice (CGTP) requirements.